Amid the recent volatility driven by geopolitical tensions and fluctuating energy prices, Asian markets have been navigating a complex landscape that has influenced investor sentiment across the region. As investors seek opportunities in this environment, identifying stocks that may be priced below their estimated value can be an effective strategy for capitalizing on potential market inefficiencies.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
STI (KOSDAQ:A039440) |
â‚©30750.00 |
â‚©61372.44 |
49.9% |
|
SILICON2 (KOSDAQ:A257720) |
â‚©38800.00 |
â‚©77230.39 |
49.8% |
|
Samyang Foods (KOSE:A003230) |
â‚©1183000.00 |
â‚©2353368.90 |
49.7% |
|
Sailvan Times (SZSE:301381) |
CNÂ¥19.34 |
CNÂ¥38.53 |
49.8% |
|
Maguro Group (SET:MAGURO) |
THB19.30 |
THB38.35 |
49.7% |
|
Livero (TSE:9245) |
Â¥2248.00 |
Â¥4462.03 |
49.6% |
|
JAC Recruitment (TSE:2124) |
Â¥863.00 |
Â¥1716.47 |
49.7% |
|
Guoquan Food (Shanghai) (SEHK:2517) |
HK$4.15 |
HK$8.30 |
50% |
|
EMRO (KOSDAQ:A058970) |
â‚©28600.00 |
â‚©56873.96 |
49.7% |
|
Caliway Biopharmaceuticals (TWSE:6919) |
NT$81.20 |
NT$162.33 |
50% |
Here we highlight a subset of our preferred stocks from the screener.
Overview: Shanghai MicroPort MedBot (Group) Co., Ltd. (SEHK:2252) specializes in the development and manufacturing of medical robotics solutions, with a market cap of approximately HK$26.55 billion.
Operations: Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on creating and producing medical robotics solutions, with its revenue segments reported in millions of CNÂ¥.
Estimated Discount To Fair Value: 26.7%
Shanghai MicroPort MedBot is trading 26.7% below its estimated fair value, with a discounted cash flow valuation at HK$25.74 compared to an estimated future cash flow value of HK$35.14. The company reported significant revenue growth, reaching CNY 551.07 million in 2025, up from CNY 257.25 million in the previous year, alongside a reduced net loss of CNY 249.66 million from CNY 642.41 million previously, driven by the successful commercialization of its Toumai surgical robot across global markets including India and Brazil.
Overview: Suzhou Zelgen Biopharmaceuticals Co., Ltd. is involved in the research, development, manufacture, sale, and distribution of medicines in China and has a market cap of CNÂ¥26.65 billion.
Operations: The company’s revenue primarily comes from its Pharmaceuticals segment, which generated CNÂ¥812.73 million.
Estimated Discount To Fair Value: 45.5%
Suzhou Zelgen Biopharmaceuticals is trading at CNÂ¥100.69, significantly below its estimated future cash flow value of CNÂ¥184.64, suggesting it may be undervalued based on cash flows. The company reported a substantial increase in sales to CNÂ¥812.73 million for 2025 from the previous year’s CNÂ¥532.95 million, although net losses widened slightly to CNÂ¥160.7 million from CNÂ¥137.83 million, highlighting ongoing profitability challenges despite strong revenue growth forecasts and expected market outperformance.
Overview: Nan Ya Printed Circuit Board Corporation manufactures and sells printed circuit boards (PCBs) across Taiwan, the United States, Mainland China, Korea, and internationally with a market cap of NT$362.50 billion.
Operations: The company’s revenue segments include NT$15.25 billion from Asia, NT$30.65 million from America, and NT$29.54 billion from its domestic market.
Estimated Discount To Fair Value: 28.2%
Nan Ya Printed Circuit Board is trading at NT$561, below its estimated future cash flow value of NT$781.6, highlighting potential undervaluation. The company reported a significant rise in 2025 sales to TWD 40.17 billion from TWD 32.28 billion in the previous year, with net income increasing to TWD 1.95 billion from TWD 203.73 million. Despite high share price volatility, earnings and revenue are forecasted to grow substantially above market rates annually.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2252 SHSE:688266 and TWSE:8046.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
















